Literature DB >> 32648938

The potential impacts of early secreted antigenic target of 6 kDa of Mycobacterium tuberculosis on KSHV-infected cells.

Lu Dai1, Bock-Gie Jung2, Jungang Chen1, Buka Samten2, James Craig Forrest3, Steven R Post1, Zhiqiang Qin1.   

Abstract

Kaposi's sarcoma-associated herpesvirus (KSHV) causes several human cancers, including Kaposi's sarcoma (KS) and primary effusion lymphoma, which are mostly seen in immunocompromised patients, such as human immunodefeciency virus (HIV)+ individuals. Tuberculosis (TB), caused by the bacterial pathogen Mycobacterium tuberculosis (Mtb), remains one of the deadliest infectious diseases in the world. The risk of developing TB is dramatically higher in people living with HIV than among those without HIV infection. Case reports link cutaneous or pulmonary KS in HIV+ patients with mycobacterial co-infections, however, impacts of Mtb infection or its products on KSHV-infected cells are not known. We report here that ESAT-6, a secreted Mtb virulence factor, induces viral reactivation from KSHV-infected cells. KSHV-infected pulmonary endothelial cells were resistant to ESAT-6 induced inhibition of cell growth. Our data demonstrate that Mtb virulence factors influence the biology of KSHV-infected cells, highlighting the need to study the interactions between these two pathogens commonly found in people living with HIV.
© 2020 Wiley Periodicals LLC.

Entities:  

Keywords:  ESAT-6; HIV; KSHV; Kaposi's sarcoma; mycobacterium tuberculosis

Mesh:

Substances:

Year:  2020        PMID: 32648938      PMCID: PMC7796979          DOI: 10.1002/jmv.26291

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   20.693


  27 in total

Review 1.  Kaposi sarcoma-associated herpesvirus-associated malignancies: epidemiology, pathogenesis, and advances in treatment.

Authors:  Manisha Bhutani; Mark N Polizzotto; Thomas S Uldrick; Robert Yarchoan
Journal:  Semin Oncol       Date:  2014-12-31       Impact factor: 4.929

2.  AIDS-related Kaposi's sarcoma: prospective validation of the AIDS Clinical Trials Group staging classification. AIDS Clinical Trials Group Oncology Committee.

Authors:  S E Krown; M A Testa; J Huang
Journal:  J Clin Oncol       Date:  1997-09       Impact factor: 44.544

3.  Granulomas in acquired immunodeficiency syndrome-associated cutaneous Kaposi sarcoma: evidence for a role for Mycobacterium tuberculosis.

Authors:  Pratistadevi K Ramdial; Yetish Sing; Sumeshini Subrayan; Eduardo Calonje; Jamila Aboobaker; Clive Sydney; Dinesh Sookdeo; Amsha Ramburan; Thandinkosi E Madiba
Journal:  J Cutan Pathol       Date:  2010-03-29       Impact factor: 1.587

Review 4.  Kaposi sarcoma-associated herpesvirus/human herpesvirus 8-associated lymphoproliferative disorders.

Authors:  Eric Oksenhendler; David Boutboul; Lionel Galicier
Journal:  Blood       Date:  2019-01-04       Impact factor: 22.113

Review 5.  Imaging manifestations of Kaposi sarcoma.

Authors:  Carlos S Restrepo; Santiago Martínez; Julio A Lemos; Jorge A Carrillo; Diego F Lemos; Paulina Ojeda; Prakash Koshy
Journal:  Radiographics       Date:  2006 Jul-Aug       Impact factor: 5.333

6.  The primary mechanism of attenuation of bacillus Calmette-Guerin is a loss of secreted lytic function required for invasion of lung interstitial tissue.

Authors:  Tsungda Hsu; Suzanne M Hingley-Wilson; Bing Chen; Mei Chen; Annie Z Dai; Paul M Morin; Carolyn B Marks; Jeevan Padiyar; Celia Goulding; Mari Gingery; David Eisenberg; Robert G Russell; Steven C Derrick; Frank M Collins; Sheldon L Morris; C Harold King; William R Jacobs
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-13       Impact factor: 11.205

7.  Early secreted antigenic target of 6-kDa protein of Mycobacterium tuberculosis primes dendritic cells to stimulate Th17 and inhibit Th1 immune responses.

Authors:  Xisheng Wang; Peter F Barnes; Fangfang Huang; Ivana B Alvarez; Pierre F Neuenschwander; David R Sherman; Buka Samten
Journal:  J Immunol       Date:  2012-08-17       Impact factor: 5.422

8.  Lymphatic reprogramming by Kaposi sarcoma herpes virus promotes the oncogenic activity of the virus-encoded G-protein-coupled receptor.

Authors:  Berenice Aguilar; Inho Choi; Dongwon Choi; Hee Kyoung Chung; Sunju Lee; Jaehyuk Yoo; Yong Suk Lee; Yong Sun Maeng; Ha Neul Lee; Eunkyung Park; Kyu Eui Kim; Nam Yoon Kim; Jae Myung Baik; Jae U Jung; Chester J Koh; Young-Kwon Hong
Journal:  Cancer Res       Date:  2012-08-31       Impact factor: 12.701

9.  Kaposi's Sarcoma Associated Herpesvirus Entry into Target Cells.

Authors:  Sayan Chakraborty; Mohanan Valiya Veettil; Bala Chandran
Journal:  Front Microbiol       Date:  2012-01-20       Impact factor: 5.640

10.  Identification of new antiviral agents against Kaposi's sarcoma-associated herpesvirus (KSHV) by high-throughput drug screening reveals the role of histamine-related signaling in promoting viral lytic reactivation.

Authors:  Jungang Chen; Lu Dai; Alana Goldstein; Haiwei Zhang; Wei Tang; J Craig Forrest; Steven R Post; Xulin Chen; Zhiqiang Qin
Journal:  PLoS Pathog       Date:  2019-12-02       Impact factor: 6.823

View more
  1 in total

Review 1.  Regulation of KSHV Latency and Lytic Reactivation.

Authors:  Grant Broussard; Blossom Damania
Journal:  Viruses       Date:  2020-09-17       Impact factor: 5.048

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.